Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a fixed-dose combination ophthalmic formulation containing carboxymethylcellulose (CMC) and cyclosporine A. Carboxymethylcellulose is a lubricating agent commonly used as an artificial tear to relieve dryness and irritation of the ocular surface. Cyclosporine A is an immunosuppressant that acts as a calcineurin inhibitor, reducing inflammation on the ocular surface by inhibiting T-cell activation. The combination is primarily used for the management of dry eye disease (DED), where CMC provides symptomatic relief through lubrication, while cyclosporine A addresses underlying inflammatory processes to improve tear production and ocular surface health[1][2]. Clinical studies have shown that this combination can improve both objective signs (such as conjunctival staining and tear break-up time) and subjective symptoms in patients with dry eye disease[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carboxymethylcellulose + cyclosporine A.